Solu Therapeutics
Boston
About Solu Therapeutics
Solu Therapeutics develops medicines designed to eliminate disease-causing proteins using a proprietary degradable warhead platform. The company focuses on engineering biologics that can bind to targeted extracellular proteins and trigger their selective degradation. Solu Therapeutics combines biologic drug design with targeted protein degradation technologies to address conditions that are not responsive to traditional therapeutic approaches. The platform involves a novel strategy for linking antibodies to protein-degrading components, aiming to extend therapeutic reach. The company’s research is centered around applications in immunology, oncology, and other disease areas driven by pathogenic proteins. Solu Therapeutics also works on optimizing pharmacokinetics and safety profiles for its biologics to enhance clinical potential. Its development pipeline includes preclinical programs advancing toward investigational new drug applications.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Total funding: $72.0M
- Funding stage: Early Stage Venture
- Last round: Series A (Apr 2025)
- Website: solutherapeutics.com
- Phone: (781) 874-1100
Industries & Categories
Biotechnology, Medical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/solu-therapeutics-17507 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.